Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).

Dr Li on the Rationale of the MoonRISe-1 Trial in NMIBC

Roger Li, MD, a genitourinary oncologist at Moffitt Cancer Center, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820) examining TAR-210 vs intravesical chemotherapy in patients with non–muscle-invasive bladder cancer.

News

® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses. 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Urothelial Cancer

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.